Claudin-18 Is a Sensitive and a Specific Marker for Gastric Neuroendocrine Tumors
Introduction: Antibody-based cancer therapies are emerging as promising therapeutics in oncology, including one in clinical trials that targets claudin-18, a protein expressed in normal gastric epithelium and some gastric adenocarcinoma. We currently have no markers for gastric well-differentiated neuroendocrine tumors (NETs).
Aim(s): We evaluated claudin-18 expression in neuroendocrine hyperplasia in autoimmune metaplastic atrophic gastritis (AMAG), gastric NETs and other organ NETs to investigate claudin-18 expression profile in gastric NETs.
Materials and methods: Seven gastric neuroendocrine hyperplasia with AMAG biopsies, eleven gastric NETs biopsies and resections, two tissue microarrays (TMA) of NETs (including NETs of gastric (4), pancreatic (26), small bowel (24), colorectal (7), appendiceal (6), and lung (25) origin) were stained with claudin-18 (CLDN18 (43-14A), Ventana Medical Systems).
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.